Alto Neuroscience/$ANRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alto Neuroscience
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Ticker
$ANRO
Sector
Primary listing
NYSE
Employees
68
Headquarters
Website
ANRO Metrics
BasicAdvanced
$640M
-
-$2.19
2.59
-
Price and volume
Market cap
$640M
Beta
2.59
52-week high
$25.17
52-week low
$1.60
Average daily volume
274K
Financial strength
Current ratio
15.693
Quick ratio
15.584
Long term debt to equity
14.703
Total debt to equity
15.851
Interest coverage (TTM)
-26.88%
Profitability
EBITDA (TTM)
-65.703
Management effectiveness
Return on assets (TTM)
-22.90%
Return on equity (TTM)
-41.80%
Valuation
Price to book
4.23
Price to tangible book (TTM)
4.23
Price to free cash flow (TTM)
-11.152
Free cash flow yield (TTM)
-8.97%
Free cash flow per share (TTM)
-1.795
Growth
Earnings per share change (TTM)
-12.22%
3-year earnings per share growth (CAGR)
-35.16%
What the Analysts think about ANRO
Analyst ratings (Buy, Hold, Sell) for Alto Neuroscience stock.
ANRO Financial Performance
Revenues and expenses
ANRO Earnings Performance
Company profitability
ANRO News
AllArticlesVideos
Alto Neuroscience Announces $120 Million Private Placement Financing
Business Wire·1 week ago
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
Business Wire·1 week ago
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alto Neuroscience stock?
Alto Neuroscience (ANRO) has a market cap of $640M as of March 24, 2026.
What is the P/E ratio for Alto Neuroscience stock?
The price to earnings (P/E) ratio for Alto Neuroscience (ANRO) stock is 0 as of March 24, 2026.
Does Alto Neuroscience stock pay dividends?
No, Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders as of March 24, 2026.
When is the next Alto Neuroscience dividend payment date?
Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Alto Neuroscience?
Alto Neuroscience (ANRO) has a beta rating of 2.59. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.